Professor Wenderlein addresses the important and interesting subject of neuroprotective and preventive measures for intervention in the pathophysiological processes of Parkinson's disease.

Idiopathic Parkinson's disease (PD) is the most common cause of parkinsonism, and dopaminergic agents provide important benefits in terms of relief of motor symptoms. By contrast, 5-10% of cases ...

AI-powered blood test detects Parkinson's disease years before symptoms appear, revolutionizing early diagnosis and treatment ...

AD: Autonomic dysfunction; DaT: Dopamine transporter; MIBG: Metaiodobenzylguanidine; PD: Parkinson's disease ... to diagnose a clinically possible idiopathic PD. A clinically probable PD might ...

It is believed, however, that idiopathic Parkinson’s disease is linked to a body’s problems with using a certain protein.

The Phase 1b open-label trial will assess the safety and tolerability of 13.5 mg/kg/day of GT-02287 for three months in patients with GBA1-PD or idiopathic Parkinson’s disease. Secondary endpoints ...

The Phase 1b open-label trial will assess the safety and tolerability of 13.5 mg/kg/day of GT-02287 for three months in patients with GBA1-PD or idiopathic Parkinson’s disease. Secondary ...